rs956572 — BCL2

BCL2 and the Brain's Survival Signal — Why One Intronic Variant Shapes Neuronal Resilience

Every neuron in your brain is engaged in a constant molecular negotiation between survival and self-destruction. The BCL2 gene — officially BCL2 Apoptosis Regulator — is one of the most important referees of that negotiation. Originally discovered at a chromosomal translocation breakpoint in follicular lymphoma in 1984, BCL2 protein sits at the outer mitochondrial membrane and blocks the cascade of events leading to apoptosis¹¹ apoptosis
Programmed cell death — the controlled self-destruction of a cell that occurs in normal development and in response to stress, infection, or DNA damage. Critically different from necrosis, which is uncontrolled cell death. In neurons, where cell division is rare and replacement is limited, BCL2-mediated survival matters enormously.

The rs956572 variant sits in a large intron of the BCL2 gene — it doesn't change any amino acid, but it influences how much BCL2 protein the cell produces. This seemingly small regulatory effect has measurable consequences on brain structure, intracellular calcium balance, and psychiatric vulnerability, making it one of the more biologically interpretable intronic variants in the mental health genetics literature.

The Mechanism

The intronic location of rs956572 at the 3′ end of BCL2's large intron places it in a regulatory region that influences mRNA and protein output. The A allele is associated with reduced BCL2 expression: lymphoblastoid cell studies by Machado-Vieira and colleagues²² Machado-Vieira and colleagues
Machado-Vieira R et al. The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder. Biol Psychiatry, 2011 found that AA genotype cells produce approximately 50% less BCL2 protein than GG cells.

BCL2 has a second, less-appreciated function beyond blocking apoptosis: it directly interacts with the inositol 1,4,5-trisphosphate receptor (IP3R)³³ inositol 1,4,5-trisphosphate receptor (IP3R)
A calcium channel on the endoplasmic reticulum membrane. When stimulated by the second-messenger IP3, it releases calcium from ER stores into the cytoplasm. BCL2 sits adjacent to this channel and limits how much calcium is released on the endoplasmic reticulum membrane, acting as a brake on calcium release from intracellular stores. When BCL2 expression falls, this brake weakens — and cells release excessive calcium into the cytoplasm in response to stimulation. This cytosolic calcium spike can activate enzymes, alter gene expression, and, if severe, trigger apoptosis.

In the AA genotype, lower BCL2 means larger, more prolonged calcium transients following IP3R stimulation. Critically, when Machado-Vieira's group treated AA cells with a BCL2-inhibitory drug, the GG cells began to look like AA cells — confirming the mechanism is BCL2-mediated, not coincidental.

The Evidence

Brain structure in healthy adults. The first indication that this variant matters came from a 2009 MRI study by Salvadore and colleagues⁴⁴ Salvadore and colleagues
Salvadore G et al. Bcl-2 Polymorphism Influences Gray Matter Volume in the Ventral Striatum in Healthy Humans. Biol Psychiatry, 2009 showing that A-allele carriers had 17.4% lower gray matter volume in the left ventral striatum compared to GG homozygotes (p_corrected = .01). The ventral striatum — home of the nucleus accumbens — is central to reward processing and emotional regulation.

A 2013 longitudinal analysis in 330 healthy adults extended this finding to aging: Liu and colleagues⁵⁵ Liu and colleagues
Liu ME et al. Effect of Bcl-2 rs956572 Polymorphism on Age-Related Gray Matter Volume Changes. PLOS One, 2013 found that A-allele carriers showed significantly steeper gray matter volume decline with aging across five brain regions — right cerebellum, bilateral lingual gyrus, right middle temporal gyrus, and right parahippocampal gyrus — while GG homozygotes showed no significant age-related change in any of these regions (most significant effect: F(1,328) = 13.77, p < .0001 in the right cerebellum).

Calcium dysregulation in bipolar disorder. In a 2011 cell study of 18 bipolar I patients, Machado-Vieira et al.⁶⁶ Machado-Vieira et al.
Machado-Vieira R et al. 2011 showed that AA cells had the highest ER calcium release upon IP3R stimulation, AG cells showed intermediate release, and GG cells had the lowest — a clean dose-response relationship. Lithium treatment normalized calcium handling in AA cells, providing a mechanistic explanation for lithium's anti-manic and mood-stabilizing effects and raising the possibility that AA carriers may be particularly lithium-responsive.

A separate case-control study of 315 individuals by Uemura and colleagues⁷⁷ Uemura and colleagues
Uemura T et al. Bcl-2 SNP rs956572 associates with disrupted intracellular calcium homeostasis in bipolar I disorder. Biol Psychiatry, 2011 examined whether BCL2 rs956572 and the L-type calcium channel variant CACNA1C rs1006737 interact. The study found both variants independently associated with calcium dysregulation in bipolar I disorder — with no statistically significant interaction term — suggesting they operate through distinct mechanisms (ER release vs. voltage-gated influx respectively) that can additively compound calcium burden.

Brain glutamate. Using magnetic resonance spectroscopy⁸⁸ magnetic resonance spectroscopy
A non-invasive brain scanning technique that measures chemical metabolite concentrations in specific brain regions. Can quantify glutamate, GABA, NAA, creatine, and other neurochemicals without exposing subjects to radiation in 40 euthymic bipolar I patients and 40 healthy controls, Green and colleagues⁹⁹ Green and colleagues
Green MJ et al. Bcl-2 rs956572 Polymorphism is Associated with Increased Anterior Cingulate Cortical Glutamate in Euthymic Bipolar I Disorder. Neuropsychopharmacology, 2013 found that AA-genotype bipolar patients had significantly elevated anterior cingulate cortex glutamate levels relative to other genotypes, and relative to healthy AA controls. Glutamate excess in the ACC is a proposed biomarker of bipolar disorder and may reflect downstream consequences of BCL2's calcium regulatory role.

Alzheimer's disease. A 2018 neuroimaging study of 104 early-stage Alzheimer's disease patients found that rs956572 genotype shaped which structural brain networks were most affected — AA homozygotes showed larger covariance effects in executive control networks, GG carriers in default mode networks — suggesting the variant modulates how neurodegeneration propagates through the brain's architecture.

Practical Implications

The most actionable implication for carriers of the A allele is to protect the molecular survival signaling that BCL2 normally provides. This means supporting mitochondrial health and limiting the cellular stressors that trigger apoptotic cascades. Omega-3 fatty acids (EPA and DHA) have direct effects on neuronal membrane fluidity and calcium channel regulation; EPA in particular reduces neuroinflammation in a way that partially compensates for reduced BCL2-mediated protection. Magnesium¹⁰¹⁰ Magnesium
An essential mineral that functions as a natural calcium channel antagonist — it competes with calcium at NMDA receptors and voltage-gated channels, reducing excessive calcium influx glycinate or threonate supports this by moderating the calcium dysregulation that a lower-BCL2 state promotes.

For individuals with a personal or family history of bipolar disorder who also carry the AA genotype, it may be worth discussing with a psychiatrist whether lithium treatment — which demonstrated the ability to normalize AA-genotype calcium dysregulation in cell studies — would be appropriate as part of a mood-stabilization strategy.

Interactions

The CACNA1C gene (rs1006737) encodes an L-type voltage-gated calcium channel and represents a convergent pathway to calcium dysregulation by a completely different mechanism. While the two variants do not statistically interact (their effects are additive and independent), individuals carrying risk alleles at both loci face calcium dysregulation from two distinct angles — excess ER calcium release via BCL2 and excess voltage-gated calcium influx via CACNA1C. Both variants are independently associated with bipolar I disorder risk and intracellular calcium elevation. Carriers of both risk genotypes represent a population with the strongest evidence for calcium-targeting interventions.